Delaying the inevitable: Are disease modifying drugs for progressive MS worthwhile?

Joachim Burman

Multiple sclerosis and related disorders 2021 Sep

filter terms:

Ocrelizumab and siponimod have a scientifically proven effect in progressive MS and decrease the risk of disability in the short-term. The primary endpoints in the pivotal trials of ocrelizumab and siponimod were reported as a hazard ratio of 3-month confirmed disability progression, which was reported to be 0.76-0.79. Based on this, both drugs were subsequently licensed for use in patients with progressive multiple sclerosis. Hazard ratios are not easily communicated to patients and therefore the alternative endpoint average postponement of disability was calculated with data from the pivotal trials. After two years of treatment, the average postponement of disability was 16 days per year with ocrelizumab and 19 days with siponimod. Over time, the average postponement of disability reached a plateau, when further treatment added little value. Taken together, these data suggest that these interventions have a short-lived and limited clinical effect in patients with progressive MS. Copyright © 2021 Elsevier B.V. All rights reserved.

Citation

Joachim Burman. Delaying the inevitable: Are disease modifying drugs for progressive MS worthwhile? Multiple sclerosis and related disorders. 2021 Sep;54:103134